Clinical trials
Autoimmune clinical trials
Below are recruiting autoimmune clinical trials, each written for real people, not researchers. We’re tracking 348 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06797024Recruiting
Study of JY231 injection for tough nerve immune disorders
This trial tests a new injection called JY231 for people with certain hard-to-treat nerve and immune disorders that haven't improved with standard treatments. It aims to see if this experimental therapy can help control the disease when other options have failed.
Wuhan, HubeiAges 18–75 - NCT06801119RecruitingPhase 1
HN2301 for autoimmune diseases study
This trial tests a new mRNA treatment called HN2301 for people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. It aims to see if the treatment is safe and helps control the disease.
Hefei, AnhuiAges 18–69 - NCT06817889RecruitingPhase 2
Remdesivir for RSV in people with weak immune systems
This trial tests if remdesivir can safely treat RSV (a respiratory virus) in people with weakened immune systems, such as those who have had a stem cell or bone marrow transplant, CAR T-cell therapy, or are being treated for blood cancer. If you have a confirmed RSV infection in your nose or throat and are at moderate or high risk for complications, you may be able to join.
Duarte, CaliforniaAges 18 years+ - NCT06826430RecruitingPhase 1
CAR-T cell therapy for severe lupus-related low platelets
This trial tests a new CAR-T cell treatment called Inaticabtagene Autoleucel for people with lupus that causes very low platelet counts (immune thrombocytopenia) that hasn't gotten better with standard treatments. The goal is to see if it can help raise platelet levels.
Beijing, Beijing MunicipalityAges 18–70 - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80 - NCT06863974Recruiting
Finding markers of relapsing nerve inflammation in children
This study looks at children who have had a first attack of nerve inflammation (like ADEM, vision loss, or spinal cord issues) to find markers in the blood that might show if it will come back. It tests blood and cells to better understand the immune response.
AngersAges 18 years+ - NCT06866652Recruiting
Why Am I Short of Breath? A Study in Myasthenia Gravis
This study looks at why people with myasthenia gravis (MG) feel short of breath. It aims to understand breathing problems that happen in daily life, even when MG seems stable.
ParisAges 18 years+ - NCT06867991RecruitingPhase 3
Combination therapy for autoimmune encephalitis
This study tests if combining two medications (a B-cell depleting drug and daratumumab) can help people with autoimmune encephalitis who haven't improved with standard treatments.
Zhengzhou, HenanAges 12 years+ - NCT06872294Recruiting
Predicting IVF success with AI
This study looks at factors that might predict success in IVF. If you're under 43, using fresh semen, and have no major uterine or genetic issues, this trial may help researchers learn what leads to a better chance of pregnancy.
Pavia, PaviaAges 18–43 - NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
Redwood City, CaliforniaAges 18–70 - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06941584Recruiting
AIRE gene's role in autoimmune nerve diseases
This study looks at how the AIRE gene affects people with autoimmune nerve diseases like NMOSD, myasthenia gravis, and autoimmune encephalitis when they also have other autoimmune conditions. It may help researchers understand why some people get multiple autoimmune problems.
RomaAges 18 years+ - NCT06941675Recruiting
Automated insulin system for LADA diabetes
This trial tests a hybrid closed-loop insulin pump system for people with LADA (a slow-progressing form of autoimmune diabetes). It aims to see if the system can improve blood sugar control and reduce hypoglycemia.
Taiyuan, ShanxiAges 18–70 - NCT06978647RecruitingPhase 1
YTS109 cell therapy for stubborn autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT06980597RecruitingPhase 1
Testing OL-108 for active autoimmune diseases
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
BeijingAges 18–65 - NCT07011147Recruiting
Real-world test of automated insulin delivery in primary care
This study tests if an automated insulin delivery system (the iLet bionic pancreas) works well in real-world primary care settings for people with type 1 or type 2 diabetes. It aims to see if this technology can help manage blood sugar more easily.
Aurora, ColoradoAges 18–89 - NCT07015580Recruiting
Mouth bacteria in pancreatitis types
This study looks at the bacteria in your mouth to see if they are different in chronic pancreatitis and autoimmune pancreatitis. It might help doctors understand these diseases better.
Shanghai, Shanghai, ChinaAges 18 years+ - NCT07040774Recruiting
Study of type 1 interferonopathies in Europe
This study looks at people with a confirmed type 1 interferonopathy, a rare immune condition caused by a gene change. It aims to learn more about how the condition progresses over time.
InnsbruckAges Any age - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT07087912RecruitingPhase 4
Dengue vaccine safety in people with autoimmune rheumatic diseases
This study tests the safety and immune response of a dengue vaccine in people aged 12–59 with stable autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are on low-dose or no immune-suppressing medications. It also includes healthy volunteers for comparison.
São Paulo, São PauloAges 12–59 - NCT07093333RecruitingPhase 2
Testing a new antibody treatment for anti-NMDAR brain disease
This study tests a new medicine (ART5803) in people whose immune system attacks a brain receptor called NMDAR, causing encephalitis (brain swelling) or psychiatric symptoms. It aims to see if the medicine can reduce symptoms like confusion, memory problems, or psychosis.
SeoulAges 18–65 - NCT07103746RecruitingPhase 2
Ublituximab for antibody-positive IMNM
This study tests an investigational medication called ublituximab (an infusion) for people with a rare autoimmune muscle disease called IMNM. It aims to reduce muscle weakness and damage by targeting specific immune cells (B cells). To join, you need a recent diagnosis (within 1 year), specific antibodies, and be on limited other medications.
Birmingham, AlabamaAges 18 years+ - NCT07104565RecruitingPhase 2
Tafasitamab for autoimmune blood cell disorders
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
Glendale, ArizonaAges 18 years+ - NCT07104721RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hefei, AnhuiAges 18–65
Hear when a new Autoimmune trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autoimmune?
- Yes. Clin2 currently lists 348 recruiting autoimmune studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autoimmune trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autoimmune trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.